Hi Singhgu,
I hope you had a lovely break with family & Happy 2024!
So as far as I am aware, all data will be unblinded by the DSMB at that Part 1 analysis at 35 weeks on treatment for the first 72 patients. I’m going off the latest ASN (American Society of Nephrology) Poster, 2023 & Primary & Secondary endpoints, & that has been in discussion with the FDA. Orphan Status allows us that privilege & outlined in Investor Presentation updates.
Since ACTION3 trial design initially, there have been a few changes, maybe that is where there is some disparity in understanding & updates.
So if you look at the Primary endpoints, it’s uPCR alone at 35 weeks from baseline. Then eGFR slope at 104 weeks.
The link on DXB website:
https://dimerix.com/action3/
Have a great day.
DXB Chart, page-528
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.030(8.00%) |
Mkt cap ! $225.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.5¢ | 37.0¢ | $637.2K | 1.624M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16500 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 169113 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |